Addictive potential of novel treatments for refractory depression and anxiety

Addictive potential of novel treatments for refractory depression and anxiety

Dusan Kolar Mood Disorders Research and Treatment Service, Department of Psychiatry, Queen’s University, Kingston, Ontario, Canada Abstract: Treatment-resistant mood disorders and anxiety disorders require intensive treatment, but treatment options should balance benefits and adverse eff...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Kolar D
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Treatment resistant depression
anxiety
addiction
ketamine
cannabinoids
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/288ecd3c6a0644db91bf6cc0abc26754
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:288ecd3c6a0644db91bf6cc0abc26754
record_format dspace
spelling oai:doaj.org-article:288ecd3c6a0644db91bf6cc0abc267542021-12-02T04:11:21ZAddictive potential of novel treatments for refractory depression and anxiety1178-2021https://doaj.org/article/288ecd3c6a0644db91bf6cc0abc267542018-06-01T00:00:00Zhttps://www.dovepress.com/addictive-potential-of-novel-treatments-for-refractory-depression-and--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Dusan Kolar Mood Disorders Research and Treatment Service, Department of Psychiatry, Queen’s University, Kingston, Ontario, Canada Abstract: Treatment-resistant mood disorders and anxiety disorders require intensive treatment, but treatment options should balance benefits and adverse effects or other potential detrimental effects on patients, including the risk of developing prescription medication addiction. Some of the newer treatment modalities for mood and anxiety disorders may have similar properties to benzodiazepines. The goal of this review was to identify the potential for developing dependence on the novel treatment approaches to treatment-resistant depression and refractory anxiety disorders. PubMed, MEDLINE, PsycINFO, Ovid, Cochrane Library, and Google Scholar were searched. Ketamine is effective in improving symptoms of major depressive disorder, but with no sustained benefits. Long-term use of oral or intranasal ketamine formulations may be associated with the risk of developing dependence. Augmentation of stimulant medication is usually effective for residual symptoms of depression, but the effects are usually short lasting and there is a potential for abuse. Synthetic cannabinoids and medicinal cannabis are increasingly being prescribed for a number of medical conditions, including anxiety disorders, without enough evidence about their efficacy and with the risk of patients developing dependence. In summary, benzodiazepines, ketamine, stimulant medications, and cannabinoids have some common characteristics, including short-lasting benefits and the risk of developing prescription medication addiction with longer use. All of these treatments may raise ethical dilemmas about the appropriateness of prescribing these medications in the long run for patients with depression and anxiety disorders. Keywords: treatment-resistant depression, anxiety, addiction, ketamine, cannabinoidsKolar DDove Medical PressarticleTreatment resistant depressionanxietyaddictionketaminecannabinoidsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 1513-1519 (2018)
institution DOAJ
collection DOAJ
language EN
topic Treatment resistant depression
anxiety
addiction
ketamine
cannabinoids
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Treatment resistant depression
anxiety
addiction
ketamine
cannabinoids
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Kolar D
Addictive potential of novel treatments for refractory depression and anxiety
description Dusan Kolar Mood Disorders Research and Treatment Service, Department of Psychiatry, Queen’s University, Kingston, Ontario, Canada Abstract: Treatment-resistant mood disorders and anxiety disorders require intensive treatment, but treatment options should balance benefits and adverse effects or other potential detrimental effects on patients, including the risk of developing prescription medication addiction. Some of the newer treatment modalities for mood and anxiety disorders may have similar properties to benzodiazepines. The goal of this review was to identify the potential for developing dependence on the novel treatment approaches to treatment-resistant depression and refractory anxiety disorders. PubMed, MEDLINE, PsycINFO, Ovid, Cochrane Library, and Google Scholar were searched. Ketamine is effective in improving symptoms of major depressive disorder, but with no sustained benefits. Long-term use of oral or intranasal ketamine formulations may be associated with the risk of developing dependence. Augmentation of stimulant medication is usually effective for residual symptoms of depression, but the effects are usually short lasting and there is a potential for abuse. Synthetic cannabinoids and medicinal cannabis are increasingly being prescribed for a number of medical conditions, including anxiety disorders, without enough evidence about their efficacy and with the risk of patients developing dependence. In summary, benzodiazepines, ketamine, stimulant medications, and cannabinoids have some common characteristics, including short-lasting benefits and the risk of developing prescription medication addiction with longer use. All of these treatments may raise ethical dilemmas about the appropriateness of prescribing these medications in the long run for patients with depression and anxiety disorders. Keywords: treatment-resistant depression, anxiety, addiction, ketamine, cannabinoids
format article
author Kolar D
author_facet Kolar D
author_sort Kolar D
title Addictive potential of novel treatments for refractory depression and anxiety
title_short Addictive potential of novel treatments for refractory depression and anxiety
title_full Addictive potential of novel treatments for refractory depression and anxiety
title_fullStr Addictive potential of novel treatments for refractory depression and anxiety
title_full_unstemmed Addictive potential of novel treatments for refractory depression and anxiety
title_sort addictive potential of novel treatments for refractory depression and anxiety
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/288ecd3c6a0644db91bf6cc0abc26754
work_keys_str_mv AT kolard addictivepotentialofnoveltreatmentsforrefractorydepressionandanxiety
_version_ 1718401356079824896

Ejemplares similares